(Q34004742)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17574095%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

review article

1 reference

title

Amyotrophic lateral sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17574095%20AND%20SRC:MED&resulttype=core&format=json

amyotrophic lateral sclerosis

1 January 2020

main subject

0 references

author

Gian Domenico Borasio

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17574095%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

author name string

J D Mitchell

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17574095%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

language of work or name

English

0 references

publication date

1 June 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17574095%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17574095%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

volume

369

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17574095%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

page(s)

2031-2041

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17574095%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

issue

9578

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17574095%20AND%20SRC:MED&resulttype=core&format=json

Cognitive change in motor neurone disease/amyotrophic lateral sclerosis (MND/ALS).

1 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

The natural history of primary lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Return of the cycad hypothesis - does the amyotrophic lateral sclerosis/parkinsonism dementia complex (ALS/PDC) of Guam have new implications for global health?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Environmental risk factors for amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Amyotrophic lateral sclerosis: toxins and environment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Prospective study of military service and mortality from ALS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Prospective study of cigarette smoking and amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Analysis of factors that modify susceptibility and rate of progression in amyotrophic lateral sclerosis (ALS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

The genetics of motor neuron diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

ALS phenotypes with mutations in CHMP2B (charged multivesicular body protein 2B)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Amyotrophic lateral sclerosis severity scale

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

A rating scale for amyotrophic lateral sclerosis: description and preliminary experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

The amyotrophic lateral sclerosis assessment questionnaire (ALSAQ-40): tests of data quality, score reliability and response rate in a survey of patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Patients' assessment of quality of life instruments: a randomised study of SIP, SF-36 and SEIQoL-DW in patients with amyotrophic lateral sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Quality of life in ALS depends on factors other than strength and physical function.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Impact of spirituality and religiousness on outcomes in patients with ALS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Individual quality of life is not correlated with health-related quality of life or physical function in patients with amyotrophic lateral sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Heavy metals and trace elements in amyotrophic lateral sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

An evidence-based medicine approach to the evaluation of the role of exogenous risk factors in sporadic amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Antioxidant treatment for amyotrophic lateral sclerosis / motor neuron disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Ca2+, mitochondria and selective motoneuron vulnerability: implications for ALS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Axonal transport and neurodegenerative disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

The pathobiology of amyotrophic lateral sclerosis: a proteinopathy?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Indices of free radical activity in the cerebrospinal fluid in motor neuron disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Superoxide dismutase mutations in an unselected cohort of Scottish amyotrophic lateral sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Clustering of ALS patients in central Italy due to the occurrence of the L84F SOD1 gene mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Human CCS gene: genomic organization and exclusion as a candidate for amyotrophic lateral sclerosis (ALS).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Amyotrophic lateral sclerosis associated with mutations in the CuZn superoxide dismutase gene

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Mitochondrial involvement in amyotrophic lateral sclerosis: trigger or target?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

The role of calcium-binding proteins in selective motoneuron vulnerability in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Minocycline in amyotrophic lateral sclerosis: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

A double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parameters

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Randomized controlled phase II trial of glatiramer acetate in ALS

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

A randomized sequential trial of creatine in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

A randomized controlled trial of recombinant interferon beta-1a in ALS. Italian Amyotrophic Lateral Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Audit of outcomes in motor neuron disease (MND) patients treated with riluzole.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Promoting excellence in end-of-life care in ALS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Management strategies for patients with amyotrophic lateral sclerosis from diagnosis through death

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Standards of palliative care for patients with amyotrophic lateral sclerosis: results of a European survey

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Multidisciplinary ALS care improves quality of life in patients with ALS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Palliative care in amyotrophic lateral sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Breaking the news in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

The use of alternative medicine by patients with amyotrophic lateral sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

The course of the terminal phase in patients with amyotrophic lateral sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Amyotrophic lateral sclerosis and life-sustaining therapy: patients' desires for information, participation in decision making, and life-sustaining therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

A retrospective study of percutaneous endoscopic gastrostomy in ALS patients during the BDNF and CNTF trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Gastrostomy insertion in ALS patients with low vital capacity: respiratory support and survival

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Percutaneous radiological gastrostomy: a safe and effective method of nutritional tube placement in advanced ALS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Patients with ALS can use sensorimotor rhythms to operate a brain-computer interface.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

The use of opioids and sedatives at the end of life

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

The effect of noninvasive ventilation on ALS patients and their caregivers.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Bipap improves survival and rate of pulmonary function decline in patients with ALS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Discontinuation of mechanical ventilation in patients with amyotrophic lateral sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Efficacy of mechanical insufflation-exsufflation in medically stable patients with amyotrophic lateral sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Attitudes of patients with amyotrophic lateral sclerosis and their care givers toward assisted suicide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Prevalence of depressive disorders and change over time in late-stage ALS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Resilience and distress among amyotrophic lateral sclerosis patients and caregivers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Results of radiotherapy for drooling in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

The quality of care and symptom control--the effects on the terminal phase of ALS/MND.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Pain in motor neuron disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Euthanasia and physician-assisted suicide among patients with amyotrophic lateral sclerosis in the Netherlands.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Motor neurone disease: a hospice perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Neurophysiological measures in amyotrophic lateral sclerosis: markers of progression in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

The natural history of central motor abnormalities in amyotrophic lateral sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Cell-replacement therapy with stem cells in neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Stem-cell therapy for amyotrophic lateral sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Stem therapy for ALS: hope and reality.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Biomarkers for amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

Gene-based treatment of motor neuron diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960944-1

7 January 2021

10.1016/S0140-6736(07)60944-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17574095%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference